
Kiniksa Pharmaceuticals International, plc: updates and filings
Price
$93.53
November 19, 2026Market cap $6.9B
What Ploutos Investor adds for Kiniksa Pharmaceuticals International
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 27, 2026next Jan 28, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
July 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 27, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 27, 2026Results of operationsForm8-K
- Oct 22, 2026Officer or director changeForm8-K
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 28, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 28, 2026Results of operationsForm8-K
- May 29, 2026Shareholder voteForm8-K
- May 26, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 26, 2026Material agreement enteredForm8-K
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 1, 2026Officer or director changeForm8-K
- Apr 28, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 28, 2026Results of operationsForm8-K
- Apr 16, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 16, 2026Additional annual meeting materialFormDEFA14A
- Apr 16, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 24, 2026Shares registered for employeesFormS-8
- Feb 24, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 24, 2026Results of operationsForm8-K
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 14, 2026Officer or director changeForm8-K
- Jan 12, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 27, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 27, 2026 | 8-K | Results of operations | Document |
| Oct 22, 2026 | 8-K | Officer or director change | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 28, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 28, 2026 | 8-K | Results of operations | Document |
| May 29, 2026 | 8-K | Shareholder vote | Document |
| May 26, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 26, 2026 | 8-K | Material agreement entered | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 1, 2026 | 8-K | Officer or director change | Document |
| Apr 28, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 28, 2026 | 8-K | Results of operations | Document |
| Apr 16, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 16, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 16, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 24, 2026 | S-8 | Shares registered for employees | Document |
| Feb 24, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 24, 2026 | 8-K | Results of operations | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 14, 2026 | 8-K | Officer or director change | Document |
| Jan 12, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 27, 2018.
The full analysis
What do Kiniksa Pharmaceuticals International's filings show?
The filings are where every one of Kiniksa Pharmaceuticals International's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.